In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Hold rating on Pacira Pharmaceuticals (NASDAQ: PCRX), with a price target of $43. The company’s shares opened today at $45.55, close to its 52-week high of $47.55.
According to TipRanks.com, Koffler is a 5-star analyst with an average return of 12.0% and a 48.4% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Eagle Pharmaceuticals Inc, and Adamas Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pacira Pharmaceuticals with a $50.83 average price target, which is an 11.6% upside from current levels. In a report released yesterday, Merrill Lynch also downgraded the stock to Hold with a $46 price target.
.
See today’s analyst top recommended stocks >>
Based on Pacira Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $2.56 million. In comparison, last year the company had a GAAP net loss of $19.74 million.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacira Pharmaceuticals, Inc. is a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients.
